Through a series of retrospective analysis, it is hoped that an objective evaluation of the effect and safety of Eucalyptol, Limonene and Pinene Enteric Soft Capsules in the treatment of community-acquired pneumonia can be made.
Study Type
OBSERVATIONAL
Enrollment
10,000
Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP\_ONLY and EXP\_ONLY cohort
Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB\_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB\_ONLY cohort
Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP\_ONLY and EXP\_ONLY cohort
Peking University Peoples Hospital
Beijing, Beijing Municipality, China
RECRUITINGGuangdong Provincial People's Hospital
Guangzhou, Guangdong, China
RECRUITINGThe First Affiliated Hospital Of Guangzhou Medical University
Guangzhou, Guangdong, China
Rate of cough-related symptoms improvement
Rate of cough-related symptoms improvement in the expectorant treatment of inpatients with community-acquired pneumonia. Compared the differences of the rates of cough improvement between the experiment group and the control group. The cough-related symptoms are evaluated and recorded in the inpatients' medical records. All the descriptions of cough-related symptoms and assessments in every inpatient's medical records will be captured.
Time frame: 7 days
Rate of overal cure and improvement in pneumonia treatment
The overal pneumonia treatment results, include cured, improved, dead and other states, are assessed and recorded in the discharge summaries. The overal cure and improvement rate calculation in every group is based on the cured and improved states.
Time frame: Up to 30 days
Hospitalization length of stay
The mean hospitalization length of stay in every group is analyzed according the discharge summaries.
Time frame: Up to 30 days
Rate of pulmonary imageological improvement
The pulmonary imageological resultes include improved, deteriorative and unchanged states. The improvement rate calculation in every group is based on the improved state according to the last imageological reports before discharge.
Time frame: Up to 30 days
Rate of normalization of vital signs
The vital signs, include temperature, pulse and respirations, are measured during the pre and post treatment. The normalization rate of vital signs is analyzed among the patients with abnormal vital signs measurements before treatment.
Time frame: 7 days
Rate of normalization of inflammatory index of pneumonia
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
RECRUITINGZhongnan Hospital of Wuhan University
Wuhan, Hubei, China
RECRUITINGRuijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
RECRUITINGShanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGThe Inflammatory indexes of pneumonia, include CRP, PCT, SAA, WBC, IL-6 and lymphocyte count, are measured during the pre and post treatment. The normalization rates of inflammatory indexes of pneumonia are analyzed among the patients with abnormal indexes measurements before treatment
Time frame: 7 days
Safety assessment: adverse events
Assess safety through monitoring of adverse events, and the collection of conventional laboratory data. All the adverse events during the pre and post treatment will be captured.
Time frame: Up to 30 days after first dose
Cost-effectiveness ratio
The all-cause healthcare will be determined by all the costs happened during the whole hospital stays (i.e.,skilled nursing facility, total medical, prescriptions). Effectiveness will be measured by the primary outcome, the rate of cough-related symptoms improvement within 7 days. The cost-effectiveness ratio is determined by the ratio of the all-cause healthcare to the rate of cough-related symptoms improvement within 7 days.
Time frame: Up to 30 days